Shoulder Joint Injection

Evidence at a Glance

"Shoulder injection" is not one procedure but several, and the injected target determines the code. The glenohumeral joint and the subacromial-subdeltoid bursa are major structures (20610/20611); the acromioclavicular (AC) joint is an intermediate joint (20605/20606); the biceps tendon sheath is coded differently again. The single most common shoulder billing error is coding an AC-joint injection as a major-joint injection. As with the hip and shoulder generally, hyaluronic acid is not covered for the shoulder - it remains a knee-only therapy.

Domain	Summary
Medicare NCD	No national coverage determination specific to shoulder injection. Corticosteroid/anesthetic injection is broadly covered when medically necessary.
Medicare LCD / Article	MAC joint-injection policies set diagnosis and frequency parameters. Hyaluronan LCDs cover the knee only; shoulder viscosupplementation is denied as investigational.
Commercial Coverage	Corticosteroid injection covered as medically necessary for qualifying shoulder pathology refractory to conservative care. Shoulder hyaluronic acid is generally non-covered.
Evidence Level	Moderate for corticosteroid short-term relief in subacromial impingement/bursitis, adhesive capsulitis, and glenohumeral osteoarthritis; image guidance improves injection accuracy.
Image Guidance	Optional. Landmark injection is common; ultrasound improves accuracy for the glenohumeral joint and biceps sheath. Ultrasound is reported with 20611/20606; fluoroscopy with 20610 plus 77002.
Prior Authorization	Corticosteroid injection usually not prior-authorized. Verify plan-specific rules; shoulder hyaluronic acid is denied regardless.
Conservative Therapy	Document activity modification, physical therapy, and analgesics/NSAIDs before injection to support medical necessity.
Diagnostic Block	Recognized use: a subacromial anesthetic response supports impingement diagnosis; an intra-articular response supports a glenohumeral source.
Key Documentation	The specific target (glenohumeral / subacromial bursa / AC joint / biceps sheath), laterality, guidance modality, injectate and units, and pre-/post pain scores.
Approval Considerations	Target-correct code (major vs intermediate), laterality-specific diagnosis, distinct-structure modifiers when multiple targets are injected, and documented conservative care.

Procedure Overview

Shoulder injections deliver corticosteroid and/or anesthetic to one of several distinct targets depending on the pain generator: the glenohumeral joint for osteoarthritis or adhesive capsulitis, the subacromial-subdeltoid bursa for impingement and bursitis, the acromioclavicular joint for AC arthropathy, or the biceps tendon sheath for bicipital tendinopathy. Each target has a characteristic clinical presentation, and each may be approached by landmark technique or under ultrasound guidance.

The operational lesson is that documentation of the target is not a clinical nicety - it is the coding determinant. A note that says only "shoulder injection" cannot be coded accurately, because the glenohumeral joint and subacromial bursa are major structures while the AC joint is intermediate. When more than one target is injected in the same session, the record must establish that they are distinct structures approached with separate needles so the claim can be reported and unbundled correctly.

Relevant Anatomy (High-Level)

The clinically and operationally relevant structures are the glenohumeral joint (the true shoulder joint, where the humeral head meets the glenoid), the subacromial-subdeltoid bursa beneath the acromion, the acromioclavicular joint between the clavicle and acromion, and the biceps tendon and its sheath. The glenohumeral joint and AC joint are separated by the joint capsule and are anatomically distinct, which is why injecting both in one session can be separately reportable when distinct needles are used. Recognizing which structure is the pain source - and documenting it precisely - drives both correct treatment and correct coding.

Clinical Indications

Glenohumeral osteoarthritis or inflammatory arthropathy with intra-articular pain.
Adhesive capsulitis (frozen shoulder) for intra-articular corticosteroid.
Subacromial impingement syndrome or subacromial-subdeltoid bursitis.
Rotator cuff tendinopathy contributing to subacromial pain (injection targets the bursa, not the tendon).
Acromioclavicular joint arthropathy with focal AC pain.
Bicipital tendinopathy involving the biceps tendon sheath.
Symptoms persisting despite documented conservative care.

Patient Selection

Selection hinges on localizing the pain generator so the correct target is injected and coded:

Examination localizing pain to a specific structure (glenohumeral, subacromial, AC, or biceps), with corroborating provocative tests.
Imaging consistent with the suspected pathology where indicated.
A documented trial of, or contraindication to, conservative management.
Functional impairment the injection is intended to improve.
A clear plan when multiple structures are symptomatic, including whether one or more targets will be injected and why.

Contraindications

Absolute	Relative
Overlying infection; suspected septic joint or bursa.	Therapeutic anticoagulation or coagulopathy (individualized).
Known allergy to the planned injectate.	Poorly controlled diabetes (corticosteroid glycemic effect).
Patient refusal or inability to cooperate.	Full-thickness rotator cuff tear where corticosteroid may be inadvisable.

Recent same-structure corticosteroid injection (cumulative risk).

Medical Necessity

Medical necessity is established by documenting the pain generator, the failure of conservative care, and the therapeutic goal. Payers expect:

The specific target and a diagnosis consistent with it (for example subacromial bursitis for a subacromial injection).
Laterality of the affected shoulder.
A documented conservative-care trial and outcome, or a contraindication.
The purpose of the injection (therapeutic and/or diagnostic) and any anesthetic response.
The functional deficit treated and the therapeutic goal.
When multiple structures are injected, the distinct-structure rationale.

Medicare Coverage Guidance

No National Coverage Determination is specific to shoulder injection. Coverage principles:

Corticosteroid / anesthetic injection. Covered when medically necessary under MAC joint-injection policy, with diagnosis and frequency parameters.
Target-based coding. Report the code matching the structure: major (20610/20611) for glenohumeral and subacromial bursa; intermediate (20605/20606) for AC joint.
Single unit per structure. Report one unit per joint or bursa per encounter, even if aspiration and injection are both performed.
Multiple structures. Distinct structures injected with separate needles may be separately reportable using a distinct-service or separate-structure modifier; documentation must support distinctness, and NCCI edits apply.
Image guidance. Ultrasound is reported with 20611/20606 (bundled, retained image required); fluoroscopy with 20610 plus 77002.
Hyaluronic acid. Not covered for the shoulder; hyaluronan coverage is knee-only.

Commercial Payer Comparison

Payer / Program	Typical Posture on Shoulder Injection
eviCore / Carelon / Cohere / Evolent	Corticosteroid joint/bursa injections generally not managed by interventional-pain UM programs; verify any musculoskeletal-management delegation.
Cigna	Covered for qualifying shoulder pathology refractory to conservative care; viscosupplementation policies restrict coverage to the knee.
Aetna	Considers corticosteroid shoulder injection medically necessary for documented pathology; shoulder hyaluronic acid considered experimental.
UnitedHealthcare	Covers corticosteroid injection under medical policy; its hyaluronic-acid drug policy limits coverage to the knee.
Humana	Medicare Advantage aligns with CMS/MAC principles; commercial follows medical-necessity criteria with frequency edits.
Blue Cross Blue Shield plans	Plan-specific policies; corticosteroid injection covered for qualifying pathology; shoulder viscosupplementation non-covered. Verify the local licensee policy.

Documentation Requirements

Specific target (glenohumeral / subacromial / AC / biceps sheath).
Laterality (right / left) documented.
Diagnosis consistent with the target injected.
Conservative therapy history and outcome.
Guidance modality (landmark / ultrasound / fluoroscopy).
For ultrasound: permanent image and report retained.
Injectate name, concentration, and units.
Pre-injection numeric pain score.
For multiple targets: distinct structures and separate needles.
Post-injection pain score and immediate percent relief.
Functional impairment and therapeutic goal.
Signed and dated procedure note.

Imaging Requirements

Diagnostic imaging (radiographs, ultrasound, or MRI) supports the specific diagnosis and excludes competing pathology, such as distinguishing glenohumeral osteoarthritis from subacromial impingement or a rotator cuff tear. Procedural guidance is optional for the shoulder because most targets are accessible by landmark technique, though ultrasound improves accuracy for the glenohumeral joint and biceps sheath and allows real-time confirmation. Ultrasound-guided injections are reported with 20611 (major) or 20606 (intermediate), which bundle the guidance and require a retained image; fluoroscopy is reported as 20610 plus 77002. The guidance decision and its rationale should be documented.

Prior Authorization Workflow

Benefit verification. Confirm coverage for corticosteroid injection and any guidance; confirm shoulder hyaluronic acid is non-covered before offering it.
Target identification. Determine and document the specific structure to be injected before the encounter where possible.
Diagnosis validation. Confirm a laterality-specific diagnosis consistent with the target.
Conservative-care confirmation. Verify the documented trial satisfies the payer's expectation.
Guidance decision. Map the modality to the correct code (20611/20606 for ultrasound; 20610 plus 77002 for fluoroscopy).
Procedure and coding. Report one unit per structure; for multiple distinct structures, apply the appropriate distinct-service or separate-structure modifier with supporting documentation.
Post-service integrity. Ensure target, laterality, guidance, and pre-/post pain scores are recorded.

Common Prior Authorization & Claim Denials

Denial Reason	Root Cause / Prevention
AC joint coded as major joint	20610 billed for an AC-joint injection. The AC joint is intermediate; report 20605/20606.
Target not documented	Note says only "shoulder injection." Document the specific structure so the correct code family applies.
Multiple structures bundled	Two targets billed without a distinct-structure modifier or documentation. Use the appropriate modifier and document separate structures/needles.
Shoulder hyaluronic acid billed	Viscosupplementation is knee-only. Do not bill shoulder HA; drug and injection deny.
Unspecified laterality / diagnosis mismatch	Diagnosis not laterality-specific or inconsistent with the target. Code laterality and match diagnosis to target.
20610 billed when ultrasound was used	Ultrasound-guided injection must be reported with 20611 (or 20606 for the AC joint). Map guidance to code.
Multiple units for one structure	More than one unit for the same structure/encounter. Report a single unit per structure.
Missing pre/post assessment	Record lacks documented pain scores. Capture pre-/post scores and percent relief.

Appeal Strategies

Submit the procedure note documenting the specific target, laterality, guidance modality, injectate and units, and pre-/post pain scores.
For AC-joint denials, confirm the intermediate-joint code (20605/20606) and resubmit if a major-joint code was used in error.
For multiple-structure denials, supply documentation of distinct structures and separate needles and apply the appropriate modifier.
For guidance denials, supply the retained ultrasound image and rationale.
For conservative-care denials, attach the documented therapy trial and outcome.
Do not appeal shoulder hyaluronic-acid denials on medical-necessity grounds; the non-coverage is categorical.

Coding & Billing Overview

Applicable CPT® Codes by Target

CPT®	Descriptor / Target	Application
20610 / 20611	Major joint or bursa (without / with ultrasound)	Glenohumeral joint; subacromial-subdeltoid bursa.
20605 / 20606	Intermediate joint or bursa (without / with ultrasound)	Acromioclavicular joint; sternoclavicular joint.
20550	Injection, single tendon sheath, or ligament, aponeurosis	Biceps tendon sheath injection.
77002	Fluoroscopic guidance for needle placement (add-on)	With 20610 when fluoroscopy is used.

HCPCS (Injectate)

Corticosteroid is reported with the appropriate J-code (for example J1030 methylprednisolone acetate 40 mg, or J3301 triamcinolone acetonide per 10 mg) on the same claim. Local anesthetics are frequently not separately payable. Hyaluronic acid supply codes apply to the knee only and should not be reported for the shoulder.

Common ICD-10-CM Diagnosis Codes

Code	Description	Typical Target
M19.011 / M19.012	Primary osteoarthritis, right / left shoulder	Glenohumeral joint.
M75.01 / M75.02	Adhesive capsulitis, right / left shoulder	Glenohumeral joint.
M75.41 / M75.42	Impingement syndrome, right / left shoulder	Subacromial bursa.
M75.51 / M75.52	Bursitis, right / left shoulder	Subacromial bursa.
M75.21 / M75.22	Bicipital tendinitis, right / left shoulder	Biceps sheath.
M25.511 / M25.512	Pain in right / left shoulder	When specific diagnosis not established.

Modifiers, POS & ASC

Element	Guidance
Modifier 59 / X{EPSU}	For a distinct second structure injected in the same session (X{S} = separate structure); document distinctness.
Modifier RT / LT	Identify the shoulder; Medicare uses RT and LT on separate lines for bilateral.
Modifier 50	For non-Medicare payers that require it for bilateral injection.
Modifier 25	For a significant, separately identifiable E/M on the same day.
Place of Service	POS 11 (office) typical; POS 22 or 24 where applicable.
ASC considerations	Predominantly office-based; ASC use is uncommon.

Clinical Documentation Checklist

Specific target documented.
Laterality (RT / LT).
Diagnosis matched to target.
Conservative therapy trial and outcome.
Guidance modality and image retained (if ultrasound).
Injectate name, concentration, units.
Distinct structures / separate needles (if multiple).
Pre-injection numeric pain score.
Post-injection pain score and percent relief.
Correct code family (major / intermediate / tendon sheath).
Distinct-service modifier applied where appropriate.
No shoulder hyaluronic acid billed.

Procedure Comparison

Target	Typical CPT®	Common Diagnosis	Notes
Glenohumeral joint	20610 / 20611	M19.01- / M75.0-	Major joint; intra-articular.
Subacromial bursa	20610 / 20611	M75.4- / M75.5-	Major bursa; named in descriptor.
Acromioclavicular joint	20605 / 20606	Shoulder-region OA	Intermediate joint - not 20610.
Biceps tendon sheath	20550	M75.2-	Tendon sheath injection.

GoHealthcare Clinical Insights

Make the target a required field. Because the injected structure determines the code family, a shoulder-injection note template should force explicit selection of glenohumeral joint, subacromial bursa, AC joint, or biceps sheath. This one control eliminates the most common shoulder coding errors, including the AC-as-major-joint mistake. Document distinctness before billing two targets. When two structures are injected, the record must show separate needles and distinct structures. Without that documentation, the second line bundles and denies regardless of the modifier applied. Match diagnosis to target. A subacromial injection paired with a glenohumeral osteoarthritis code invites scrutiny. Align the diagnosis with the structure actually injected.

GoHealthcare Leadership Perspective

The shoulder is the clearest example in this series of anatomy driving reimbursement. A single clinical phrase - "shoulder injection" - can map to three different code families and two different reimbursement tiers depending on the target. The organizational risk is a documentation habit that under-specifies the structure and leaves coders to guess. The leadership priorities are a template that forces target selection, a coding rule that routes the AC and sternoclavicular joints to the intermediate codes, a documented distinct-structure standard for multi-target sessions, and a categorical block on shoulder hyaluronic acid. These convert an anatomically complex, error-prone service into a precise, defensible one.

GoHealthcare Prior Authorization Insight

The authorization insight for the shoulder is that the risk is coding precision rather than authorization friction. Corticosteroid shoulder injections rarely require prior authorization, but they routinely deny for target-coding and distinct-structure errors that no authorization step would have caught. Our quality-assurance approach verifies target-to-code alignment, diagnosis-to-target consistency, and distinct-structure documentation before the claim drops, and excludes shoulder hyaluronic acid categorically. This retrospective-authorization discipline prevents the precise coding errors that account for most shoulder-injection revenue loss.

GoHealthcare Case Study

The following case is a composite created for education. It does not depict any actual patient or organization.

Clinical Scenario

A patient with combined subacromial impingement and acromioclavicular arthropathy underwent same-session injection of the subacromial bursa and the AC joint. The practice billed two units of 20610 with a single shoulder-pain diagnosis and no distinct-structure modifier.

Documentation & Coding Challenges

The claim denied. The AC-joint injection should have been reported as an intermediate-joint code (20605), not a second 20610; the two lines lacked a distinct-structure modifier and documentation of separate needles; and the generic shoulder-pain diagnosis did not match either specific target.

Payer & Prior Authorization Barriers

Corticosteroid injection required no prior authorization, so no checkpoint had validated the target-to-code alignment or the distinct-structure documentation before submission.

Resolution Strategy

The practice recoded the AC injection to 20605, matched each line to its specific diagnosis (subacromial bursitis and AC arthropathy), applied a separate-structure modifier with documentation of separate needles, and resubmitted. Prospectively, it built a target-selection field into the note template and a coding rule routing the AC joint to the intermediate code.

Outcome & Lessons Learned

The corrected claim was paid, and shoulder-injection denials fell in the following quarter. The lesson: shoulder-injection accuracy depends on documenting the target and its distinctness, and on routing each structure to its correct code family

- controls that operate independently of any authorization requirement.

GoHealthcare Best Practices

Require explicit target selection (glenohumeral / subacromial / AC / biceps sheath) in the note template.
Route the AC and sternoclavicular joints to the intermediate codes (20605/20606).
Document distinct structures and separate needles before billing multiple targets, with the appropriate modifier.
Match the diagnosis to the specific target and specify laterality.
Map guidance to code (20611/20606 for ultrasound; 20610 plus 77002 for fluoroscopy) and retain images.
Block hyaluronic acid on shoulder diagnoses at the claim-edit level.

Common Mistakes

Coding an AC-joint injection as a major-joint injection (20610 instead of 20605).
Documenting only "shoulder injection" without the specific target.
Billing two targets without distinct-structure documentation or modifier.
Reporting shoulder hyaluronic acid, which is non-covered.
Using a generic or mismatched diagnosis for a specific target.
Reporting 20610 plus 76942 for an ultrasound-guided injection instead of 20611.
Reporting multiple units for a single structure.
Omitting laterality or pre-/post pain scores.

Pearls and Pitfalls

Pearls	Pitfalls
Document the exact structure injected.	Leaving the target as "shoulder" and forcing a guess.
Route the AC joint to the intermediate code.	Defaulting every shoulder injection to 20610.
Document distinct structures before billing two targets.	Billing two lines with no distinctness support.
Match each diagnosis to its target.	Pairing a subacromial injection with a glenohumeral code.
Exclude shoulder hyaluronic acid categorically.	Billing shoulder viscosupplementation and losing the injection too.

Frequently Asked Questions

What code is used for a glenohumeral (intra-articular shoulder) injection?

20610 (without ultrasound) or 20611 (with ultrasound). The glenohumeral joint is a major joint.

What code is used for a subacromial bursa injection?

20610 or 20611. The subacromial bursa is a major bursa and is specifically named in the descriptor.

What code is used for an AC-joint injection?

20605 (without ultrasound) or 20606 (with ultrasound). The acromioclavicular joint is an intermediate joint, not a major joint.

Why is coding the AC joint as 20610 wrong?

The AC joint is intermediate, so it maps to 20605/20606. Billing 20610 is the most common shoulder coding error and a frequent denial.

How is a biceps tendon sheath injection coded?

With 20550 (injection of a single tendon sheath), which is distinct from the joint/bursa codes.

Can I bill two shoulder injections in the same session?

Yes, when two distinct structures are injected with separate needles (for example glenohumeral joint and subacromial bursa, or glenohumeral and AC joints). Append a distinct-service or separate-structure modifier and document distinctness; NCCI edits apply.

Is hyaluronic acid covered for the shoulder?

No. Hyaluronic acid is FDA-approved and covered for the knee only; shoulder viscosupplementation is off-label and non-covered.

Is image guidance required for shoulder injection?

No. Most targets are accessible by landmark technique. Ultrasound improves accuracy for the glenohumeral joint and biceps sheath; report 20611/20606 when it is used and documented.

How do I code ultrasound guidance?

Report 20611 (major) or 20606 (AC joint), which bundle the ultrasound guidance and require a retained image. Do not add 76942.

What ICD-10 codes are used?

Match the diagnosis to the target: M19.01- (glenohumeral OA), M75.0- (adhesive capsulitis), M75.4- (impingement), M75.5- (bursitis), M75.2- (bicipital tendinitis), with laterality.

Does the diagnosis need to match the target?

Yes. A subacromial injection should carry a subacromial diagnosis (for example M75.5-), not a glenohumeral osteoarthritis code.

How many units per structure?

One unit per joint or bursa per encounter, even if aspiration and injection are both performed.

How is bilateral shoulder injection reported?

Medicare reports RT on one line and LT on a second; non-Medicare payers may require modifier 50.

Does shoulder injection require prior authorization?

Corticosteroid injection usually does not. Verify plan rules; shoulder hyaluronic acid is non-covered regardless.

Is conservative care required first?

Frequently. Document a conservative-care trial and outcome, or a contraindication, before injection.

Can a shoulder injection be diagnostic?

Yes. A subacromial anesthetic response supports impingement; an intra-articular response supports a glenohumeral source. Document the response.

Should corticosteroid be used with a full-thickness cuff tear?

It may be inadvisable; document the assessment and clinical rationale.

What place of service applies?

POS 11 (office) is typical; POS 22 or 24 where applicable.

What is the sternoclavicular joint code?

The sternoclavicular joint is intermediate; report 20605/20606, as with the AC joint.

What single control most reduces shoulder-injection denials?

A required target-selection field in the note template that drives correct code-family selection.

Can rotator cuff tendinopathy be injected directly?

Injection typically targets the subacromial bursa rather than the tendon itself; document the structure injected accordingly.

Why did my two-injection claim deny?

Common causes are coding the AC joint as major, missing distinct-structure documentation or modifier, or mismatched diagnoses. Correct and resubmit.

Key Takeaways

The injected target determines the code: glenohumeral and subacromial bursa are major (20610/20611); the AC and sternoclavicular joints are intermediate (20605/20606); the biceps sheath is 20550.
Coding the AC joint as a major joint is the most common shoulder billing error.
Document the specific target on every shoulder-injection note.
For multiple targets, document distinct structures and separate needles and apply a distinct-service modifier.
Match the diagnosis to the target and specify laterality.
Hyaluronic acid is not covered for the shoulder.
Ultrasound guidance is bundled into 20611/20606; do not add 76942.

Future Outlook

Ultrasound guidance for shoulder injection will continue to expand, improving accuracy for the glenohumeral joint and biceps sheath and reinforcing the importance of image retention for the guided codes. Coding scrutiny of target specificity and multi-structure billing is likely to increase as payers refine distinct-service edits. Corticosteroid shoulder injection will remain a stable, covered service, while shoulder viscosupplementation remains investigational absent FDA approval. Practices that enforce target-based documentation and coding now will adapt smoothly as these edits tighten.

References

American Medical Association. CPT® 2026 Professional Edition (20550, 20605, 20606, 20610, 20611, 77002). https://www.ama-assn.org/practice-management/cpt KZA. Coding Coaches - Acromioclavicular Joint Billing (AC joint is intermediate; 20605/20606). https://www.kzanow.com/coding-coaches/acromioclavicular-joint-billing AAPC. Problem Code 20610 (joint size; separate reporting of GH and AC injections). https://www.aapc.com/blog/27495-problem-code-20610/American College of Emergency Physicians (ACEP). Arthrocentesis & Injection FAQ (joint-size codes; permanent image requirement). https://www.acep.org/administration/reimbursement/reimbursement-faqs/Arthrocentesis-Injection-faq ICD-10-CM 2026, M75.- (Shoulder lesions) and M19.01- (Primary OA of shoulder). https://www.icd10data.com/ICD10CM/Codes/M00-M99/M70-M79/M75-Centers for Medicare & Medicaid Services. Medicare Coverage Database (joint-injection LCDs/articles by MAC; hyaluronan knee-only). https://www.cms.gov/medicare-coverage-database American Academy of Orthopaedic Surgeons (AAOS). https://www.aaos.org American Medical Society for Sports Medicine (AMSSM). https://www.amssm.org

Reading Recommendations

AMA CPT® guidance on joint-size code selection and ultrasound-guidance requirements.
Your MAC's joint-injection LCD/article and hyaluronan knee-only policy.
NCCI policy manual sections on distinct-service reporting for multiple structures.
AAOS and sports-medicine guidance on shoulder injection targets and technique.

Recommended Downloads

Shoulder Injection Structured Note Template (with required target field).
Target-to-Code Quick-Reference (glenohumeral / subacromial / AC / biceps).
Distinct-Structure Documentation Checklist (multi-target sessions).
Shoulder Hyaluronic-Acid Hard-Stop Claim-Edit Specification.

Visual Recommendations

High-level illustration of shoulder injection targets (glenohumeral, subacromial, AC, biceps sheath).
Target-to-code decision tree (major / intermediate / tendon sheath).
Multi-structure billing decision flow with distinct-service modifiers.
Diagnosis-to-target matching matrix.
Coding matrix: 20610 / 20611 / 20605 / 20606 / 20550 with modifiers.
Documentation checklist infographic for point-of-care use.

Educational Disclaimer

This document is intended for educational and operational reference purposes only. It does not replace physician clinical judgment, payer policy review, legal advice, or official CMS guidance, and it is not a procedural or physician training manual. Coverage policies, coding guidance, frequency limitations, and reimbursement requirements change frequently and vary by payer, plan, and jurisdiction; all codes and coverage criteria must be independently verified against the applicable payer policy and current regulatory sources before submission. CPT® is a registered trademark of the American Medical Association. GoHealthcare Practice Solutions assumes no liability for actions taken in reliance on this educational material.

This webpage does not replace physician judgment, official payer policy, legal advice, or current coding guidance. CPT® is a registered trademark of the American Medical Association.